Jerryx Junior Syrup is a combination pharmaceutical formulation containing Levosalbutamol (0.5 mg/5 ml), Ambroxol (15 mg/5 ml), and Guaifenesin (50 mg/5 ml), designed for pediatric use in the management of respiratory conditions characterized by bronchospasm, mucus hypersecretion, and productive cough. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts as a bronchodilator by relaxing the smooth muscles of the airways, thereby facilitating easier breathing in conditions such as asthma and bronchitis. Ambroxol serves as a mucolytic agent, enhancing the clearance of mucus by breaking down the structure of sputum, which aids in alleviating congestion and improving respiratory function. Guaifenesin is an expectorant that promotes the thinning and loosening of mucus in the airways, facilitating its expulsion through coughing. The synergistic action of these active ingredients makes Jerryx Junior Syrup effective in relieving symptoms associated with acute and chronic respiratory tract infections in children. It should be administered according to the prescribed dosage, and caution is advised in patients with hypersensitivity to any component. Use under medical supervision is recommended to ensure safety and efficacy.